EMERGENT-5: Cobenfy and Treatment Durability
From Psychopharmacology and Psychiatry Updates · · 12 min
This plays from the publisher's own server. We do not host a copy.
Description
In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial tracking Cobenfy's real-world durability and safety in schizophrenia. We explore whether early symptom gains hold up over time, what side effects persist, and why blood pressure monitoring now deserves a permanent spot on your checklist.
Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.5 CME: Quick Take Vol. 85
- Xanomeline-Trospium Long-Term: Does Efficacy and Safety Hold Up After One Year?
Back to Psychopharmacology and Psychiatry Updates · Report a problem